We are live on ! Find out more
SVA

Sinovac Biotech, Ltd
SVA

Delisted

SVA was delisted on the 22nd of February, 2019.

Back to rankings

30 hedge funds and large institutions have $44.3M invested in Sinovac Biotech, Ltd in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less capital invested

Capital invested by funds: $44.4M → $44.3M (-$40.8K)

3% less funds holding

Funds holding: 31 → 30 (-1)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
30
Holders Change
-1
Holders Change %
-3.23%
% of All Funds
0.52%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
–
Increased
2
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$1.3K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$46.8K
2
Wells Fargo
Wells Fargo
California
-$8.15K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.29K
4
FGAM
Financial Gravity Asset Management
Texas
-$796
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
1
Vivo Capital
California
$38.2M – – –
NAH
2
Neumann Advisory (HK)
Hong Kong
$2.04M – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$1.54M – – –
State Street
4
State Street
Massachusetts
$1.04M – – –
YMRC
5
Yorktown Management & Research Company
Virginia
$485K – – –
O
6
OrbiMed
New York
$341K – – –
Skandinaviska Enskilda Banken (SEB)
7
Skandinaviska Enskilda Banken (SEB)
Sweden
$259K – – –
Geode Capital Management
8
Geode Capital Management
Massachusetts
$179K – – –
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$106K -$1.29K -200 -1%
Northern Trust
10
Northern Trust
Illinois
$55K – – –
Group One Trading
11
Group One Trading
Illinois
$27K – – –
Morgan Stanley
12
Morgan Stanley
New York
$27K +$1.3K +200 +5%
JP Morgan Chase
13
JP Morgan Chase
New York
$19K – – –
UBS Group
14
UBS Group
Switzerland
$14K -$46.8K -7,000 -77%
Wells Fargo
15
Wells Fargo
California
$11K -$8.15K -1,250 -43%
IA
16
IFP Advisors
Florida
$8K – – –
CS
17
Credit Suisse
Switzerland
$1K – – –
Northwestern Mutual Wealth Management
18
Northwestern Mutual Wealth Management
Wisconsin
$1K – – –
FGAM
19
Financial Gravity Asset Management
Texas
– -$796 -144 Closed

SVA Hedge Fund Activity: Q3 2022 in Review

30 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q3 2022, worth a combined $44.3M — down 0.09% from $44.4M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of SVA and 0 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 2 added.

The largest buyer was Morgan Stanley, adding an estimated $1.3K. The largest seller was UBS Group, cutting an estimated $46.8K.

  • 30 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q3 2022, down from 31 in Q2 2022.
  • Funds reported $44.3M of Sinovac Biotech, Ltd stock for Q3 2022, down 0.09% quarter-over-quarter.
  • 0 funds opened new Sinovac Biotech, Ltd positions in Q3 2022 and 1 closed out, a net change of -1 holder.
  • The largest Sinovac Biotech, Ltd buyer in Q3 2022 was Morgan Stanley, an estimated $1.3K added.
  • The largest Sinovac Biotech, Ltd seller in Q3 2022 was UBS Group, an estimated $46.8K sold.

Based on aggregated 13F filings for Q3 2022.